IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Recurrent Vaginal Cancer
Dana-Farber Cancer Institutemonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Recurrent Vaginal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Durvalumab M.D. Anderson Cancer Center | Phase 2 | B |
Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 M.D. Anderson Cancer Center | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Plasmid Encoded Il-12 M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →